Abstract
controls were seen only for Hormone Bother (pZ0.02) and all Sexual domains (p 70, Gleason 8-10, post-PT year >5. None of the other Summary scores showed clinically significant differences regardless of PT subset. Conclusions: Men treated with PT for PCa had similar QOL scores compared to controls except in Sexual domains and in Hormone-Bother sub-domain. Clinically significant differences were primarily seen in sexual domains and related to HT use, older age, higher Gleason sum, and longer interval from treatment. No difference was seen in Bowel or Urinary QOL compared to men without PCa. Author Disclosure: A.K. Lee: None. L.B. Levy: None. C.J. Rossi: None. D.A. Bush: None. S. Choi: None. N.P. Mendenhall: None. Q.N. Nguyen: None. S. Keole: L. Stock Options; ProCure. A.L. Zietman: None. J.D. Slater: None.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
